Xilio Therapeutics Inc (XLO)
1.18
-0.08
(-6.35%)
USD |
NASDAQ |
May 10, 16:00
1.15
-0.03
(-2.54%)
After-Hours: 20:00
Xilio Therapeutics Cash from Investing (TTM): -0.486M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.486M |
September 30, 2023 | -0.995M |
June 30, 2023 | -1.328M |
March 31, 2023 | -1.783M |
December 31, 2022 | -1.867M |
Date | Value |
---|---|
September 30, 2022 | -1.736M |
June 30, 2022 | -1.517M |
March 31, 2022 | -1.184M |
December 31, 2021 | -1.10M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-1.867M
Minimum
Dec 2022
-0.486M
Maximum
Dec 2023
-1.333M
Average
-1.328M
Median
Jun 2023
Cash from Investing (TTM) Benchmarks
Gilead Sciences Inc | -3.646B |
FibroGen Inc | 101.45M |
Avalo Therapeutics Inc | -0.133M |
IGM Biosciences Inc | 68.36M |
AEON Biopharma Inc | -- |